Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa

被引:77
作者
Kang, CI
Kim, SH
Park, WB
Lee, KD
Kim, HB
Kim, EC
Oh, MD
Choe, KW
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Lab Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Res Inst, Seoul, South Korea
关键词
D O I
10.1089/mdr.2005.11.68
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study was conducted to evaluate risk factors for antimicrobial resistance and influence of resistance on mortality in Pseudomonas aeruginosa bacteremia. Data on 190 patients with P. aeruginosa bacteremia were analyzed retrospectively. Antimicrobial resistance to antipseudomonal antibiotics was evaluated. The main outcome measure was 30-day mortality. In P. aeruginosa bacteremia, resistance rates to piperacillin (PIP), ceftazidime (CAZ), ciprofloxacin (CIP), and imipenem (IPM) were 29 (56/190), 19 (36/190), 17 (32/190) and 15% (28/190), respectively. Prior uses of fluoroquinolones or carbapenems were independent risk factors for resistance to CIP and IPM, and prior use of extended-spectrum cephalosporins was a risk factor for PIP-R. An indwelling urinary catheter was a risk factor for PIP-R, CAZ-R, and CIP-R. An invasive procedure was a risk factor for CIP-R and IPM-R. The 30-day mortality rate was 44% (33/75) in patients infected by strains resistant to any of the antipseudomonal antibiotics, but 33.9% (39/115) in those by strains susceptible to all antipseudomonal antibiotics (p = 0.161). Among patients with bloodstream infection due to antimicrobial-resistant P. aeruginosa, those infected by IPM-R strains had the highest mortality (IPM-R, 53.6% vs. CAZ-R, 47.2% vs. CIP-R 46.9%, PIP-R, 39.3%). In this study regarding P. aeruginosa bacteremia, prior uses of fluoroquinolones, carbapenems, or extended-spectrum cephalosporins, a prior invasive procedure, and an indwelling urinary catheter were found to be associated with antimicrobial resistance. The patients with bloodstream infection caused by antimicrobial-resistant P. aeruginosa, especially to imipenem, had a tendency toward higher mortality than those infected by susceptible strains.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 24 条
  • [1] Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: Clinical outcome and length of hospitalization
    Blot, S
    Vandewoude, K
    De Bacquer, D
    Colardyn, F
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) : 1600 - 1606
  • [2] Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
    Carmeli, Y
    Troillet, N
    Karchmer, AW
    Samore, MH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) : 1127 - 1132
  • [3] Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents
    Carmeli, Y
    Troillet, N
    Eliopoulos, GM
    Samore, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1379 - 1382
  • [4] Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer -: Retrospective analysis of 245 episodes
    Chatzinikolaou, I
    Abi-Said, D
    Bodey, GP
    Rolston, KVI
    Tarrand, JJ
    Samonis, G
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) : 501 - 509
  • [5] El Amari EB, 2001, CLIN INFECT DIS, V33, P1859, DOI 10.1086/324346
  • [6] Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter:: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000
    Friedland, I
    Stinson, L
    Ikaiddi, M
    Harm, S
    Woods, GL
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (04) : 245 - 250
  • [7] CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988
    GARNER, JS
    JARVIS, WR
    EMORI, TG
    HORAN, TC
    HUGHES, JM
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) : 128 - 140
  • [8] Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa
    Harris, A
    Torres-Viera, C
    Venkataraman, L
    DeGirolami, P
    Samore, M
    Carmeli, Y
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) : 1128 - 1133
  • [9] Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients
    Harris, AD
    Perencevich, E
    Roghmann, MC
    Morris, G
    Kaye, KS
    Johnson, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 854 - 858
  • [10] Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients
    Harris, AD
    Smith, D
    Johnson, JA
    Bradham, DD
    Roghmann, MC
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) : 340 - 345